Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?

@article{Ahn2018DoLI,
  title={Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?},
  author={Rosa Ahn and Vinay K. Prasad},
  journal={Cardiovascular Drugs and Therapy},
  year={2018},
  volume={32},
  pages={633-635}
}
  • Rosa AhnV. Prasad
  • Published 19 September 2018
  • Medicine
  • Cardiovascular Drugs and Therapy
On July 07, 2015, the US Food and Drug Administration approved sacubitril/valsartan (Entresto, Novartis) for the treatment of congestive heart failure (NYHA class II–IV). The drug was approved on the basis of a single trial, PARADIGM-HF, where 10,521 patients entered, and 8442 patients were randomized to either the combination sacubitril/valsartan or enalapril. The trial showed an impressive improvement in cardiovascular death (hazard ratio in the neprilysin group, 0.80; 95% confidence interval… 
10 Citations

Five Years of Sacubitril/Valsartan—a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance

With increased uptake of sacubitril/valsartan, risks of hypotension, renal dysfunction, hyperkalemia, and angioedema appear low and acceptable in RCTs and global clinical practice.

Efficacy and safety of sacubitril/valsartan in the treatment of heart failure: protocol for a systematic review incorporating

This review will collate all available RCT data on Discussion: sacubitril/valsartan including published and unpublished sources in order to obtain a more complete picture of the evidence base for sacubiteil/valsarta and meta-analysis for clinical efficacy and safety outcomes.

Efficacy and safety of sacubitril/valsartan in the treatment of heart failure: protocol for a systematic review incorporating unpublished clinical study reports [version 1; peer review: 3 approved]

A thorough review of the evidence base for sacubitril/valsartan, a first-in-class angiotensinreceptor neprilysin inhibitor used to treat heart failure with reduced ejection fraction, is conducted.

Efficacy and safety of sacubitril/valsartan in the treatment of heart failure: protocol for a systematic review incorporating unpublished clinical study reports.

This review will collate all available RCT data on sacubitril/valsartan including published and unpublished sources in order to obtain a more complete picture of the evidence base for sacubitsin-receptor neprilysin inhibitor.

Efficacy and safety of sacubitril/valsartan in the treatment of heart failure: protocol for a systematic review incorporating unpublished clinical study reports

All relevant clinical and safety outcomes will be reviewed, particularly hospitalisation due to heart failure and cardiovascular mortality, and Narrative synthesis of included studies will be conducted and, if appropriate, meta-analysis for clinical efficacy andSafety outcomes are conducted.

Effects of Sacubitril/Valsartan in Patients with High Arrhythmic Risk and an ICD: A Longitudinal Study

Sacubitril/valsartan therapy for HFrEF may lead to significant clinical and functional improvements even in patients with ICD at greater arrhythmic risk, especially within the first 6 months of therapy.

Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care

ARNI treatment was associated with lower risk of a composite effectiveness endpoint compared with RAS blockade alone in older adults with HFrEF.

Sacubitril/valsartan (Entresto) utilisation and prescribing patterns in the context of a reimbursement application system

The aim of this study was to evaluate the utilisation of Entresto in Ireland and compare patient characteristics to those of the pivotal PARADIGM‐HF trial.

Confirmatory Trials for Drugs Approved on a Single Trial.

Criticism of recent trials in cardiovascular medicine force us to revisit under what circumstances two regulatory trials are preferable, and when one might suffice, and a confirmatory, randomized study could provide clarity in both examples.

Recently Approved and Under Investigation Drugs for Treating Patients with Heart Failure

The aim of this manuscript is to review the main drugs under investigation for the treatment of patients with HF and give perspectives for their implementation into clinical practice.

References

SHOWING 1-7 OF 7 REFERENCES

Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA

  • M. Packer
  • Medicine, Biology
    European journal of heart failure
  • 2016
Regulatory review in the USA concluded that the established advantages of sacubitril/valsartan on cardiovascular death and disease progression outweighed hypothetical uncertainties about the long‐term effects of neprilysin inhibition in patients who might not have survived without the drug.

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

These findings indicate that patients with heart failure should not generally be maintained on very low doses of an ACE inhibitor (unless these are the only doses that can be tolerated) and suggest that the difference in efficacy between intermediate and high doses of a ACE inhibitor is likely to be very small.

SacubitrilValsartan in Heart Failure: Why Are More Physicians Not Prescribing It?

Treatment with sacubitrilvalsartan is cost-effective in reducing cardiovascular mortality and morbidity of chronic heart failure in patients with NYHA class II to IV heart failure and the cost-effectiveness analyses indicate that the drug provides excellent value.

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure and decreased the symptoms and physical limitations of heart failure.

Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis

In patients with HF with reduced ejection fraction, compared with lower doses, higher doses of ACEI and ARB significantly though modestly improved the composite end point of all-cause mortality or HF hospitalization without significantly increasing the chances of discontinuation.

Run-in periods in randomized trials: implications for the application of results in clinical practice.

Analysis of reports of clinical trials in which run-in periods were used to exclude noncompliant subjects, placebo responders, or subjects who could not tolerate or did not respond to active drug found that the reported results overestimate the benefits and underestimate the risks of treatment, underestimate the number needed to treat, and yield a smaller P value.

Uptake of new heart failure drug slow , say makers